|
BioScreening - organic compounds for screening
Biotech & Pharma Business and Investment News2009: The Year That Was For Pfizer - (RTTNews) - True to expectations, Jeffrey Kindler, the CEO of Pfizer Inc. (PFE | Quote | Chart | News | PowerRating), scripted a new playbook for the drug giant in 2009, accelerating the process of transformation by clinching the largest pharmaceutical [...]
Forma Therapeutics raises $25.5M in Series B round - Forma Therapeutics has closed on a Series B financing that raised a total of $25.5 million. The round was led by new investor Lilly Ventures. Lilly was joined by existing investors Novartis Option Fund and Bio*One Capital of Singapore. Lexington-based Cubist Pharmaceutical, Inc. also joined as a new equity investor through a conversion of a [...]
Syntopix edges closer to early revenue streams, announces positive phase II cosmetic study of antimicrobial compound - Specialty antimicrobial research and development company Syntopix (AIM: SYN) took another step closer to commercialising a new product targeting a large consumer healthcare market, reporting good results from the trials of its new compound for the treatment of acneic skin, a condition that affects 85% of the population during their lifetime.
Over the course of the [...]
GSK Signs On Astex in Broad Partnership for About $33M Up Front - GlaxoSmithKline (GSK) has inked a deal with Astex Therapeutics to discover, develop, and commercialize compounds directed against multiple targets for £20 million (about $33 million) up front. Astex is eligible to development and regulatory milestones of over £300 million (roughly $496.47 million) if all programs are successfully developed and commercialized.
The up-front payment comprises £12.5 million [...]
Commonwealth Biotechnologies, Inc. Acquisition of GL Biochem: Market Update - Shareholders approve sale of the Richmond, Virginia assets as required under the
GL Biochem Asset Purchase Agreement
RICHMOND, Va.–(Business Wire)–
Commonwealth Biotechnologies, Inc. (”CBI”) (NASDAQ Capital Market: CBTE) has
recently announced a definitive share purchase agreement to acquire
Shanghai-based GL Biochem and associated businesses (the “GL Group”), the
largest global supplier of research-grade peptide products and peptide reagents.
Management is pleased to [...]
Eurogentec Announces Agreement to Acquire AnaSpec, Inc. - Liège, Belgium—October 23, 2009.
Eurogentec S.A. (“Eurogentec”) announces today a final agreement for the acquisition of AnaSpec Inc (“AnaSpec” or the “Company”), a privately held proteomics company based in Fremont, California. Founded in 1993, AnaSpec is a leading provider of integrated proteomics solutions for life science research and diagnostics with expertise in peptides synthesis, labeled peptides [...]
DiscoveryBioMed, Inc. Awarded Phase 2 SBIR Grant by the NIH to Discover Hypertension and Cystic Fibrosis (CF) Drugs - BIRMINGHAM, Ala.–(BUSINESS WIRE)–DiscoveryBioMed, Inc. (DBM) today announced that it has been awarded a $750,000 Small Business Innovations Research (SBIR) Phase 2 grant by the National Institutes of Health (NIH) to continue the research into the [...]
Alcon to Acquire Swiss Biotechnology Firm, ESBATech AG Company gains access to proprietary antibody fragment technology particularly suited to treat eye diseases - HUENENBERG, Switzerland & ZURICH, Sep 13, 2009 (BUSINESS WIRE) — –Acquisition establishes sustainable platform for ongoing biologics development
–Deal builds on other recent transactions to expand breadth and depth of Alcon’s development opportunities in eye care in the long term
–ESBATech shareholders retain rights to non-ophthalmic technology and products
Alcon [...]
Evotec Announces Research Agreement With Biogen Idec - HAMBURG, Germany and OXFORD, UK, Sept. 9, 2009 (GLOBE NEWSWIRE) -- Evotec AG
(Frankfurt:EVT) (Nasdaq:EVTC), a leading provider in the discovery and
development of novel small molecule drugs, today announced that it has entered
into a research agreement with Biogen Idec (Nasdaq:BIIB), a leading
biopharmaceutical company headquartered in Cambridge, Mass., USA.
Evotec will use its expertise and technologies in protein [...]
Sigma-Aldrich buys ChemNavigator - Sigma-Aldrich said Thursday that it acquired ChemNavigator.com Inc., a provider of software used to identify and procure chemistry needed for drug discovery and research, for an undisclosed sum.
ChemNavigator, which has operations in San Diego and in Australia, provides chemists with virtual screening tools and products that allow them to channel their chemical designs toward sets [...]
Forma Therapeutics, Novartis team on cancer drugs - Forma Therapeutics Inc. said that it has entered into a collaboration agreement with Novartis AG to use Forma’s cell-based screening platform to discover inhibitors for undisclosed protein-protein interaction targets to help develop cancer drugs.
No financial terms of the deal were disclosed. The funding arm of pharmaceutical giant Novartis, the Novartis Option Fund, was one of [...]
Nuevolution Announces Worldwide Technology Cross-Licensing Agreement With GSK - COPENHAGEN, Denmark, July 28 /PRNewswire/ — Nuevolution today announced the execution of a worldwide technology cross-licensing agreement with GlaxoSmithKline.
The agreement relates to a number of patented technologies for rapid synthesis and DNA-tagging of hundreds of millions of chemically diverse drug-like small molecule compounds and the efficient screening of these, facilitating the identification of potent drug [...]
Forget the Shortcuts: Creating a Truly Innovative Biotech Culture - Watching the acquisition of Genentech by Roche has been a fascinating process. I wasn’t so interested in the eventual price paid per share, but whether Basel, Switzerland-based Roche, one of the oldest and most traditional pharma companies, could preserve the special science-based culture at Genentech that made it the world’s pre-eminent biotech company. Would Genentech’s [...]
Drug Approvals, Natural And Unnatural - I seem to have been putting a lot of graphics up this week, so here’s another one. This is borrowed from a recent Science paper on the future of natural-products based drug discovery. It’s interesting both from that viewpoint, and because of the general approval numbers:
And there you have it. Outside of anomalies like 2005, [...]
Horizon Discovery signs screening agreement with SuperGen Inc. - Horizon Discovery today announced it has signed a commercial agreement with US Pharmaceutical company SuperGen, Inc., relating to its X-MAN technology.
Horizon’s X-MAN (Mutant And Normal) cell-line technology provides the first genetically-defined and patient-relevant in vitro models of human cancer. These models are being used by a growing number of Pharma and Biotech companies to rationalize [...]
Ligand and GlaxoSmithKline Collaboration Identifies New Lead Compound - SAN DIEGO, Mar 30, 2009 (BUSINESS WIRE) —-Ligand Pharmaceuticals Incorporated (NASDAQ: LGND: 2.98, -0.14, -4.49%) today
announced that it has identified a new lead for advancement in its
alliance with GlaxoSmithKline (NYSE:GSK). This newly identified lead
compound is from a program being evaluated as a potential treatment for
[...]
Ligand and GlaxoSmithKline Collaboration Identifies New Lead Compound - SAN DIEGO, Mar 30, 2009 (BUSINESS WIRE) —-Ligand Pharmaceuticals Incorporated (NASDAQ: LGND: 2.98, -0.14, -4.49%) today announced that it has identified a new lead for advancement in its alliance with GlaxoSmithKline (NYSE:GSK). This newly identified lead compound is from a program being evaluated [...]
GTCbio Announces its 4th Annual Assay Development and Screening Technologies Conference taking place - The goal of the 4th annual Assay and Screening Technologies Conference is to provide a forum for academics and professionals in the drug discovery industry to stay abreast of exciting new developments in assay technologies while exchanging ideas and developing more efficient approaches to the drug discovery and development process.
[USPRwire, Thu Mar 26 2009] [...]
European Molecular Biology Laboratory (EMBL) Signs Agreement to License Themis and Surflex-Dock Technologies from Tripos - ST. LOUIS, Mo.–(BUSINESS WIRE)–Tripos™, a leading provider of drug discovery informatics products and services, today announced an agreement with the European Molecular Biology Laboratory (EMBL), Europe’s leading research institution for molecular biology, to license [...]
20 Emerging Healthcare Stocks to Watch in ‘09 - Emerging Diagnostic Index: Average loss of 63.2%, including 39 companies with average market cap of $50M
Emerging Bio-Pharma Index: Top 40 Rated Companies
Emerging Bio-Pharma Index: 36 Additional Companies
Micro-Cap Bio-Pharma Index: 130 companies with an average loss of 43.6% in past year and average market cap of $58M
AspenBio Pharma (APPY) – APPY has pending results for the [...]
|
|
